Wockhardt is currently trading at Rs. 266.00, up by 2.10 points or 0.80% from its previous closing of Rs. 263.90 on the BSE.
The scrip opened at Rs. 259.00 and has touched a high and low of Rs. 276.10 and Rs. 250.75 respectively. So far 45848 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 440.50 on 22-Apr-2019 and a 52 week low of Rs. 147.20 on 24-Mar-2020.
Last one week high and low of the scrip stood at Rs. 280.00 and Rs. 238.40 respectively. The current market cap of the company is Rs. 2966.59 crore.
The promoters holding in the company stood at 72.40%, while Institutions and Non-Institutions held 5.41% and 22.18% respectively.
Wockhardt has received Qualified Infectious Disease Product (QIDP) designation from the US health regulator for its combination antibiotic, WCK 6777. The QIDP status is granted to drugs that are effective against a set of multi-drug resistant pathogens identified by the Centre for Disease Control, USA, which have a high degree of unmet need in the treatment of patients infected by such pathogens. The company has received QIDP designation from the United States Food and Drug Administration (USFDA) for WCK 6777, a once-a-day combination antibiotic.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: